Pavigard2 mg

Pavigard is indicated as an adjunct to diet for the following:

• Primary hyperlipidemia and mixed dyslipidemia (established/approved use): to reduce elevated total cholesterol, LDL cholesterol, apolipoprotein B, triglycerides, and to increase HDL cholesterol in adult patients.
• Heterozygous familial hypercholesterolemia (HeFH) in pediatric patients aged 8 years and older (approved use): to reduce LDL cholesterol, as an adjunct to diet, in children whose LDL-C remains elevated despite dietary measures.
• Primary prevention of cardiovascular events (guideline-supported use): Pavigard and other statins are used in patients at elevated cardiovascular risk (e.g. diabetes, elevated LDL-C, additional risk factors) to reduce the risk of myocardial infarction, stroke, and revascularization procedures, based on the well-established class effect of statins rather than a dedicated outcomes trial for this specific agent.
• Secondary prevention in established atherosclerotic cardiovascular disease (guideline-supported use): used as part of comprehensive risk-factor management following myocardial infarction, stroke, or peripheral arterial disease.

Pavigard is not intended for patients requiring high-intensity LDL-lowering (e.g. very high baseline LDL-C or very high cardiovascular risk); such patients should generally receive an alternative high-intensity statin.

Each film-coated tablet contains Pitavastatin Calcium equivalent to pitavastatin as the active ingredient, commonly available in 1 mg, 2 mg, and 4 mg strengths, along with standard pharmaceutical excipients such as lactose, microcrystalline cellulose, magnesium stearate, and film-coating agents.

Pavigard is a synthetic lipid-lowering agent belonging to the statin (HMG-CoA reductase inhibitor) class. It is used to manage abnormal cholesterol and triglyceride levels and to reduce the risk of cardiovascular events in appropriately selected patients.

Pavigard is administered orally, once daily, and works primarily in the liver, where most cholesterol synthesis occurs. Its effect on LDL cholesterol is generally apparent within two weeks, with maximal effect typically achieved within four weeks of consistent use.

Pavigard belongs to the therapeutic class of lipid-lowering agents, specifically the HMG-CoA reductase inhibitors (statins).

Pitavastatin Calcium competitively inhibits 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, the rate-limiting enzyme that converts HMG-CoA to mevalonate, an early and rate-determining step in hepatic cholesterol biosynthesis.

By inhibiting this enzyme, Pitavastatin Calcium reduces intracellular cholesterol synthesis, which upregulates hepatic LDL receptor expression on the cell surface. This increases hepatic uptake and clearance of LDL cholesterol from the circulation and reduces circulating LDL-C, total cholesterol, apolipoprotein B, and triglyceride levels, while modestly raising HDL cholesterol.

Pharmacokinetics: Pitavastatin Calcium is absorbed after oral administration with an absolute bioavailability of approximately 51%, undergoes minimal hepatic metabolism (limited CYP2C9/CYP2C8 involvement, making it less prone to certain CYP3A4-mediated drug interactions compared with some other statins), and is eliminated mainly via biliary excretion with a plasma half-life of approximately 12 hours.

Pavigard tablets should be swallowed whole with water, taken orally once daily at any time of day, with or without food. Tablets should not be crushed or chewed unless the prescribing physician or pharmacist specifically advises otherwise. Consistency in daily timing is recommended to support adherence.

The following interactions with Pavigard are clinically significant and well established:

• Cyclosporine: Significantly increases pitavastatin plasma concentrations (up to several-fold), substantially raising the risk of myopathy and rhabdomyolysis. Concurrent use is contraindicated.
• Erythromycin: Increases pitavastatin exposure; if co-administration is necessary, the Pavigard dose should be limited to 1 mg once daily.
• Rifampin: Increases pitavastatin exposure via transporter inhibition; if co-administration is necessary, the Pavigard dose should be limited to 2 mg once daily.
• Fibrates (especially gemfibrozil): Concomitant use increases the risk of myopathy and rhabdomyolysis; gemfibrozil combination should generally be avoided, and other fibrates should be used cautiously with monitoring.
• Niacin (lipid-modifying doses): May increase the risk of skeletal muscle effects when combined with Pavigard; use with caution.
• Warfarin: Statins may potentiate the effect of warfarin; INR should be monitored when Pavigard is started, stopped, or dose-adjusted in patients on warfarin.

Patients should inform their physician of all prescription medicines, over-the-counter drugs, and supplements before starting Pavigard.

Most patients tolerate Pavigard well. Reported adverse effects include:

• Common: myalgia (muscle pain), back pain, diarrhea, constipation, and pain in extremities.
• Less common: headache, nausea, arthralgia, mild elevations in liver enzymes, and insomnia.
• Serious (uncommon but important): myopathy and rhabdomyolysis, presenting as unexplained muscle pain, tenderness, or weakness, particularly if accompanied by fever, malaise, or dark urine; immune-mediated necrotizing myopathy (persistent muscle weakness with elevated creatine kinase even after discontinuation); clinically significant hepatotoxicity; and a small increased risk of new-onset diabetes mellitus/hyperglycemia, particularly in patients with pre-existing risk factors.

Patients should seek prompt medical attention for unexplained muscle pain, weakness, dark urine, jaundice, or signs of an allergic reaction while taking Pavigard.

Pregnancy: Pavigard is contraindicated in pregnancy. Cholesterol and cholesterol biosynthesis are essential for fetal development, and statins, including Pavigard, may cause fetal harm when administered to a pregnant woman. There is no established benefit of continuing statin therapy during pregnancy, since it is generally used for chronic risk reduction rather than acute treatment. Pavigard should be discontinued as soon as pregnancy is recognized. Females of reproductive potential should use effective contraception while taking Pavigard and should inform their physician promptly if pregnancy occurs or is suspected.

Lactation: Pavigard is contraindicated during breastfeeding. It is not known whether Pavigard is present in human milk, but because of the potential for serious adverse reactions in a breastfed infant, women should not breastfeed while taking this medicine; a decision should be made to either discontinue breastfeeding or discontinue the drug, taking into account the importance of therapy to the mother.

The following precautions apply to the use of Pavigard:

• Myopathy and rhabdomyolysis: Risk increases with renal impairment, hypothyroidism (which should be adequately treated before or during statin therapy), advanced age (65 years and older), and concomitant use of interacting drugs (see Interactions). Patients should be advised to promptly report unexplained muscle pain, tenderness, weakness, or dark-colored urine. Pavigard should be temporarily discontinued if myopathy is suspected or diagnosed, or if markedly elevated creatine kinase levels occur.
• Hepatic effects: Persistent elevations in hepatic transaminases can occur. Liver function testing is reasonable before initiation and if signs or symptoms of liver injury occur during treatment (e.g. unusual fatigue, jaundice, dark urine, right upper quadrant pain). Pavigard is contraindicated in active liver disease (see Contraindications).
• New-onset diabetes mellitus: Statin therapy, including Pavigard, is associated with a small increase in the risk of elevated blood glucose and new-onset diabetes; the cardiovascular benefit of statin therapy generally outweighs this risk in patients with an appropriate indication, but glycemic status should be monitored per usual clinical practice.
• Females of reproductive potential: Because Pavigard is contraindicated in pregnancy, effective contraception should be used during therapy.
• Renal impairment: Requires dose adjustment (see Dosage and Administration) due to increased systemic exposure.

There is no specific antidote for Pavigard overdose. In the event of a suspected overdose, seek immediate medical attention or contact a poison control center. Treatment should be general and supportive, directed at the presenting symptoms, and clinicians may consider monitoring liver function and creatine kinase. Because Pavigard is highly protein-bound, hemodialysis is not expected to significantly enhance its clearance.

Store at room temperature (below 30°C), protected from light and moisture. Keep out of reach of children.

Pediatric use: Pavigard is approved for use in patients aged 8 years and older with heterozygous familial hypercholesterolemia, using weight/age-appropriate dosing and titration under specialist supervision. Safety and efficacy in children under 8 years of age, and in other pediatric lipid disorders, have not been established.

Geriatric use: No overall differences in effectiveness have been observed between elderly and younger patients, but elderly patients (65 years and older) are at increased risk of myopathy and should be monitored closely; a lower starting dose may be considered.

Renal impairment: Dose adjustment is required in moderate-to-severe renal impairment and in patients on hemodialysis (see Dosage and Administration).

Hepatic impairment: Pavigard is contraindicated in active liver disease, acute liver failure, or decompensated cirrhosis; use with caution and appropriate monitoring in mild hepatic impairment.

Pavigard is typically used long-term as part of ongoing management of hyperlipidemia and cardiovascular risk reduction. Treatment duration is determined by the treating physician based on lipid response, tolerability, and overall cardiovascular risk, and therapy is usually continued indefinitely unless contraindications, intolerance, or a change in clinical goals arises.

Pitavastatin Calcium belongs to the statin (HMG-CoA reductase inhibitor) class of lipid-lowering medicines.

Pitavastatin Calcium works by competitively and selectively inhibiting HMG-CoA reductase, the enzyme responsible for converting HMG-CoA to mevalonate, a key early step in hepatic cholesterol synthesis. This inhibition leads to increased expression of hepatic LDL receptors, enhancing the clearance of LDL cholesterol from the bloodstream and lowering total cholesterol, LDL-C, apolipoprotein B, and triglyceride levels.

X

Pavigard is approved for use in pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia (HeFH) who have an inadequate response to diet, using a weight/age-based starting dose titrated under specialist supervision up to a maximum of 4 mg once daily. Safety and efficacy have not been established in children younger than 8 years of age or for indications other than HeFH. Pediatric patients on Pavigard should be monitored for growth, development, and the same muscle- and liver-related adverse effects seen in adults.